Clinical Trial Update: Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

View source ↗

Summary

A clinical trial update examining how often Type I gastric neuroendocrine tumors recur after treatment with long-acting somatostatin analogs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Neuroendocrine Tumor

Drugs mentioned

• SOMATULINE DEPOT (LANREOTIDE ACETATE)
• Sandostatin LAR (octreotide)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Gastric NET | Status: UNKNOWN